SEC Comment Letter 0000000000-23-005787 to Salarius Pharmaceuticals, Inc. (SLRX) (CIK 0001615219) (DCOY)
Salarius Pharmaceuticals, Inc. (SLRX) (CIK 0001615219)
Date: June 1, 2023 · CIK: 0001615219 · Accession: 0000000000-23-005787
AI Filing Summary & Sentiment
File numbers found in text: 333-272249
Letter
United States securities and exchange commission logo June 1, 2023 Mark Rosenblum Chief Financial Officer Salarius Pharmaceuticals, Inc. 2450 Holcombe Blvd., Suite X Houston, TX 77021 Re:Salarius Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 26, 2023 File No. 333-272249 Dear Mark Rosenblum: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen M. Nicolai, Esq.
Show Raw Text
United States securities and exchange commission logo
June 1, 2023
Mark Rosenblum
Chief Financial Officer
Salarius Pharmaceuticals, Inc.
2450 Holcombe Blvd., Suite X
Houston, TX 77021
Re:Salarius Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 26, 2023
File No. 333-272249
Dear Mark Rosenblum:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Stephen M. Nicolai, Esq.